Clinical trial
A Multicenter Phase II Study of the Capecitabine, Oxaliplatin and Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer
NCT01024504 is registered in ClinicalTrials.gov with Hellenic Oncology Research Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter Phase II Study of the Capecitabine, Oxaliplatin and Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer
- Lead sponsor
- Hellenic Oncology Research Group
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 31, 2006
- Completion date
- March 31, 2010
- Enrollment
- 46 (estimated)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.
metastatic colorectal cancer